转移性黑色素瘤
黑色素瘤
医学
肿瘤浸润淋巴细胞
淋巴细胞
癌症研究
免疫学
病理
免疫疗法
免疫系统
作者
Christy Los,Sebastian Klobuch,John B.A.G. Haanen
出处
期刊:The cancer journal
[Ovid Technologies (Wolters Kluwer)]
日期:2024-03-01
卷期号:30 (2): 113-119
标识
DOI:10.1097/ppo.0000000000000705
摘要
Abstract Major progress in prolonging survival of patients with advanced melanoma has been made in the past decade because of the development and approval of immune checkpoint inhibitor and targeted therapies. However, for nonresponding or relapsing patients, their prognosis is still dismal. Based on clinical trial data, treatment with adoptive cell therapies holds great promise. In patients with metastatic melanoma progressing on or nonresponsive to single-agent anti–programmed cell death 1, infusion of tumor-infiltrating lymphocytes can produce responses in up to half of patients, with durable complete responses in up to 20%. Genetic modification of peripheral blood T cells with T-cell receptors derived from tumor-specific T cells, or with chimeric antigen receptors, has the potential to further improve treatment outcomes in this refractory population. In this review, we will discuss the historical development, current status, and future perspectives of adoptive T-cell therapies in melanoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI